Intratumoral microinfusion of nimustine (ACNU) for recurrent glioma.
We investigated stereotactic intratumoral microinfusion of nimustine (ACNU) in recurrent brain tumors. Eligibility required histologic confirmation of glioma recurrence despite standard radiotherapy and chemotherapy as well as enhancement of the recurrence with gadolinium on magnetic resonance imaging (MRI). A total intratumoral dose of 10 mg of ACNU was administered continuously with a microinfusion pump over an average of 13h. Fifteen infusions were given in nine patients. All patients completed the treatment safely. On MRI, necrotic changes surrounded the infusion area in all patients, and tumor progression was inhibited or performance score was improved in seven of nine patients. No symptomatic systemic toxicity was evident, although one patient developed permanent left oculomotor palsy locally after treatment of a left medial temporal tumor. It is concluded that direct microinfusion of ACNU into recurrent gliomas can induce tumor necrosis and inhibit tumor growth.
Wakabayashi
T
T
Department of Neurosurgery, Nagoya University School of Medicine, Japan. wakabt@tsuru.med.nagoya-u.ac.jp
Yoshida
J
J
Mizuno
M
M
Kajita
Y
Y
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D005260:Female; D005910:Glioma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D015552:Injections, Intralesional; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D015376:Nimustine / Q000008:administration & dosage* / Q000627:therapeutic use; D009837:Oligodendroglioma / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D011446:Prospective Studies
D000970:Antineoplastic Agents; D015376:Nimustine